Imatinib mesylate effect on bone marrow hematopoietic cells of chronic myeloid leukemia patients
Summary:
Analysis of bone marrow hematopoietic cells in chronic myeloid leukemia (CML) patients one month after imatinib mesylate (IM) therapy. CML is caused by expression of the BCR/ABL fusion oncogene. Results provide insight into the molecular consequences of IM blockade of oncoprotein Bcr-Abl in CML.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Benito R, Lumbreras E, Abáigar M, Gutiérrez NC et al. Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression. Pharmacogenet Genomics 2012 May;22(5):381-8. PMID: 22388797
